Sidney Taurel
Sidney Taurel
Sidney Taurelis a Moroccan-born American businessman. He is the former Chairman and Chief Executive Officer of Eli Lilly and Company. He became chief executive officer in July 1998 and chairman of the board of directors on January 1, 1999. He was succeeded as chief executive officer by John C. Lechleiter on April 1, 2008. He now serves as an advisor at Moelis & Company...
best company customer deliver help leadership people position role step sure team throughout
We want to be sure that our leadership team is in the best position to help people throughout the company deliver for the customer now and in the future. John's new role is an important step in making that happen.
commitment execution faster grow quarter rate reflect results sales strong
Our strong bottom-line results in the first quarter reflect the execution on our commitment to grow sales at a faster rate than our expenses.
applied extract higher medicare methods plans private sector
As we see the cost-containment methods being used by the private sector being now applied now to this Medicare business, I think those plans will extract higher and higher discounts from the industry,
bringing earnings half sales second stronger
As we expected, the second half of 2005 is bringing stronger sales and earnings growth,
combined continues dependent five fully growth introduced last less line major percent performance product products prozac rate sales
As our product line continues to become more diversified, we have become less dependent on Prozac performance. Major products introduced in the last five years accounted for fully one-third of our sales in 1999 and had a combined growth rate of 41 percent during the year.
economy growing region resilient seeing seems
We are seeing a very resilient economy and one that seems to be growing in every part of the world. Just about every region is growing and it's very encouraging.
expectation overall
I think there is an overall unreasonable expectation right now that there is such a thing as a risk-free drug.
existing extensions growth less line next overall product products prozac quarters recent rely sales several
Our overall growth for the next several quarters will be generated from newer product sales, line extensions of existing products and recent product launches, ... As a result, we will rely less on Prozac sales growth.
forward join leadership role senior vital
He is very well-prepared for the vital role he will play, and I look forward to having him join our senior leadership team.
earnings forward grow growth looking percent products share
Looking forward to 2006, our newer products should grow to about 24 percent of revenues and earnings per share should grow 8 to 11 percent, representing top-tier growth for large-cap pharmaceutical companies.
help means products weather
That means up to 10 products that will be launched between 2001 and 2004, which will help us weather the storm,
access increase people poor short
In the short term, I think this will increase access to some people who are not poor enough to be on Medicaid,
ability add area bar behind bench dedication drive increase leadership leaves performance pivotal raise strong throughout transform valued
Charlie's leadership was pivotal in our drive to increase productivity in every part of Lilly. His ability to transform our organization and raise the bar in every area of performance has been invaluable. His dedication to leadership development is also evident. He leaves behind a strong bench of valued leaders who add value throughout the company.
advantage attractive combined enhance focus found offer pcs rite taking value
By taking advantage of this opportunity, Lilly will be able to enhance its focus on pharmaceutical innovation, ... We found Rite Aid's offer attractive because of its value to Lilly and the many synergistic opportunities PCS will have when combined with Rite Aid.